Welcure Delivers: Pharma Firm Completes ₹3,000 Cr Export Sourcing Milestone

Image Source: HDFC Sky

Welcure Drugs & Pharmaceuticals Ltd has successfully executed exportsourcing mandates worth ₹3,000 crore, marking a major milestone in its assetlight, feebased global expansion strategy. The company, which has recently gained traction for its thirdparty procurement services, completed highvalue assignments for clients including Thailandbased Fortune Sagar Impex, Giant Exim, and Ravina International.

Key Highlights:

Welcure completed two exportsourcing orders worth ₹85.6 crore from Giant Exim and Ravina International for mycorrhizal inoculant procurement.
These assignments were structured under an ExWorks (EXW) model, eliminating inventory and logistics risks for Welcure.
The company also executed a ₹517 crore global sourcing mandate from Fortune Sagar Impex, involving procurement of finisheddosage pharmaceutical SKUs.
Combined with other mandates, the company has now crossed ₹3,000 crore in cumulative exportsourcing deals.
All contracts are feebased, with Welcure earning fixed commissions (typically 5%) on the value of goods sourced.

Strategic Significance:

The company’s model ensures highmargin, lowrisk revenue through commission income, without exposure to working capital or warehousing.
Welcure remains debtfree and is actively expanding its international sourcing portfolio.
It is in advanced talks for additional orders worth ₹20 crore or more in the current quarter.

Outlook: Welcure’s execution of largescale sourcing mandates signals growing global trust in its procurement capabilities. With a strong pipeline and a scalable, capitallight model, the company is wellpositioned to enhance profitability and shareholder value in FY26 and beyond.

Sources: The Hindu BusinessLine, Economic Times, Smart Investment, Pharma ET